Results 111 to 120 of about 21,988 (154)

Factors Associated With The Initiation Of Biologic Disease Modifying Antirheumatic Drugs In Texas Medicaid Patients With Rheumatoid Arthritis [PDF]

, 2014
G. Kim, Jamie C. Barner, KL Rascati, Kristin M. Richards   +3 more
openalex   +1 more source

Combination Therapy for Psoriasis with Methotrexate and Other Oral Disease-Modifying Antirheumatic Drugs: A Systematic Review. [PDF]

Dermatol Ther (Heidelb), 2023
Hsieh TS, Tsai TF.
europepmc   +1 more source

Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis

, 2009
Rachel O’Mahony, Mark Richards, C. Deighton, D. G. I. Scott   +3 more
openalex   +1 more source

Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs [PDF]

, 2014
Tsutomu Takeuchi, Tsukasa Matsubara, Yukitomo Urata, Eiichi Suematsu, Shuji Ohta, Shigeru Honjo, Tohru Abe, Ami Yamamoto, Nobuyuki Miyasaka   +8 more
openalex   +1 more source

Letter to the Editor Regarding: "Incidence of Malignancies and the Association with Biological Disease-Modifying Antirheumatic Drugs in Japanese Patients with Rheumatoid Arthritis: A Time-Dependent Analysis from the IORRA Patient Registry". [PDF]

Rheumatol Ther
Liu Z, Tian M, Duan L.
europepmc   +1 more source

Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis. [PDF]

Explor Res Clin Soc Pharm, 2023
Huang Y, Chatterjee S, Agarwal SK, Chen H, Johnson ML, Aparasu RR.   +5 more
europepmc   +1 more source

Lipid profiles in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs [PDF]

, 2014
Anna Filipowicz‐Sosnowska, Piotr Głuszko, Robert Rupiński   +2 more
openalex   +1 more source

Major adverse cardiovascular events or venous thromboembolism in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a nationwide, population-based cohort study. [PDF]

Ther Adv Musculoskelet Dis
Kao CM, Chen YJ, Chen YM, Chen DY, Chen HH.   +4 more
europepmc   +1 more source

Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy. [PDF]

Front Pharmacol, 2023
Convertino I, Cazzato M, Tillati S, Giometto S, Gini R, Valdiserra G, Cappello E, Ferraro S, Bonaso M, Bartolini C, Paoletti O, Lorenzoni V, Trieste L, Filippi M, Turchetti G, Cristofano M, Blandizzi C, Mosca M, Lucenteforte E, Tuccori M.   +19 more
europepmc   +1 more source

Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis [PDF]

, 2015
Shunsuke Mori
openalex   +1 more source